{"disease":{"id":"cell-therapy","name":"cell therapy"},"drugs":{"marketed":[{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"venetoclax-rituximab","indication_name":"Treatment of adult patients with CLL who have a 17p deletion and have failed a B-cell receptor (BCR) pathway inhibitor and have received at least one prior therapy and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor and have failed a B-cell receptor (BCR) pathway inhibitor.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Venetoclax; Rituximab","generic_name":"venetoclax-rituximab","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCL-2 (venetoclax); CD20 (rituximab)","drug_class":"BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)","quality_score":10,"revenue":"2583","mechanism":""},{"drug_id":"cyclophosphamide","indication_name":"Treatment prior to tumor-specific T-cell infusion therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"cyclophosphamide","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Tumor cell DNA","drug_class":"Alkylating agent","quality_score":10,"revenue":"1000.0","mechanism":"Cyclophosphamide cross-links tumor cell DNA and interferes with malignant cell growth through active alkylating metabolites."},{"drug_id":"pf-06865571","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as a monotherapy in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (≥ 50%) as a monotherapy in adults and in combination with pembrolizumab in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"chembl-chembl1200796","indication_name":"Treatment prior to tumor-specific T-cell infusion therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"CYCLOPHOSPHAMIDE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"cyclophosphamide","quality_score":10,"revenue":null,"mechanism":"Cytoxan works by interfering with the DNA replication process in rapidly dividing cancer cells."},{"drug_id":"bendamustin","indication_name":"Treatment prior to tumor-specific T-cell infusion therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Bendamustin","company_name":"Meir Medical Center","drug_phase":"marketed","molecular_target":"Histone deacetylase 1, Histone deacetylase 10, Histone deacetylase 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"etoposid","indication_name":"Treatment prior to tumor-specific T-cell infusion therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Etoposid","company_name":"University of Ulm","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Canalicular multispecific organic anion transporter 2, Multidrug resistance-associated protein 6","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"etoposide","indication_name":"Treatment prior to tumor-specific T-cell infusion therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vepesid","generic_name":"etoposide","company_name":"Bristol-Myers Squibb K.K.","drug_phase":"marketed","molecular_target":"DNA topoisomerase 2-alpha","drug_class":"Topoisomerase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"bendamustine","indication_name":"Treatment prior to tumor-specific T-cell infusion therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Treanda","generic_name":"BENDAMUSTINE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Histone deacetylase 6","drug_class":"Alkylating Drug","quality_score":63,"revenue":null,"mechanism":"Treanda works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and grow."},{"drug_id":"pf-06823859","indication_name":"Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (Tumor Proportion Score (TPS) ≥ 50%) as monotherapy (pembrolizumab in combination with pemetrexed and platinum (pemetrexed + platinum) in patients with a PD-L1 TPS ≥ 1% as determined by an FDA-approved test.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"pf-06823859","indication_name":"Squamous Cell Carcinoma of the Head and Neck (SCCHN) with disease progression on or after platinum-containing chemotherapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06823859","generic_name":"pf-06823859","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1","drug_class":"Monoclonal Antibody","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"irinotecan-carboplatin-erbitux","indication_name":"First-line treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) in combination with 5-fluorouracil and radiation therapy.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"irinotecan + Carboplatin + erbitux","generic_name":"irinotecan-carboplatin-erbitux","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"topoisomerase I, platinum DNA damage, epidermal growth factor receptor","drug_class":"chemotherapy","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cyclophosphamid","indication_name":"Treatment prior to tumor-specific T-cell infusion therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cyclophosphamid","company_name":"Zhejiang University","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"inavolisib","indication_name":"Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least two prior lines of therapy for whom MAb-based therapy has failed","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Itovebi","generic_name":"inavolisib","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"phosphatidylinositol 3-kinase (PI3K) alpha (PIK3CA)","drug_class":"Kinase Inhibitor [EPC]","quality_score":80,"revenue":null,"mechanism":"Inavolisib is a PI3K inhibitor with degradative activity against PI3Kα."},{"drug_id":"daratumumab-and-hyaluronidase-fihj","indication_name":"Multiple Myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Darzalex Faspro","generic_name":"daratumumab-and-hyaluronidase-fihj","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CD38","drug_class":"CD38-directed Cytolytic Antibody [EPC]","quality_score":63,"revenue":null,"mechanism":"Daratumumab and Hyaluronidase-fihj is a monoclonal antibody that targets CD38, a transmembrane glycoprotein on the surface of hematopoietic cells."},{"drug_id":"tocilizumab","indication_name":"Cytokine release syndrome induced by tumor-specific T-cell infusion therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Roactemra","generic_name":"tocilizumab","company_name":"Roche","drug_phase":"marketed","molecular_target":"Interleukin-6 receptor","drug_class":"Interleukin-6 Receptor Antagonist [EPC]","quality_score":10,"revenue":null,"mechanism":"Roactemra works by blocking the interleukin-6 receptor, a protein that plays a key role in inflammation."},{"drug_id":"89zr-zr-crefmirlimab-berdoxam","indication_name":"Plaquenil-resistant or -intolerant adult patients with cutaneous T-cell lymphoma (CTCL) who have had an inadequate response or are intolerant to at least one prior systemic therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"[89Zr]Zr-crefmirlimab berdoxam","generic_name":"89zr-zr-crefmirlimab-berdoxam","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Fibroblast Activation Protein (FAP)","drug_class":"Radiolabeled Monoclonal Antibody","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"axitinib-ag-013736","indication_name":"Advanced renal cell carcinoma (RCC) after failure of prior therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Axitinib (AG-013736)","generic_name":"axitinib-ag-013736","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"vascular endothelial growth factor receptors (VEGFRs)","drug_class":"tyrosine kinase inhibitor","quality_score":45,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"olaparib-200-300-mg-bid-daily","indication_name":"Small-cell lung cancer (olaparib + low-dose radiotherapy)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olaparib 200-300 mg BID, daily","company_name":"Repare Therapeutics","drug_phase":"discontinued","molecular_target":"PARP1 and PARP2 (poly(ADP-ribose) polymerase enzymes)","drug_class":"PARP inhibitor (DNA damage response inhibitor)","quality_score":null,"revenue":null,"mechanism":"Olaparib inhibits PARP enzymes to block DNA single-strand break repair, inducing synthetic lethality in BRCA-mutant and HR-deficient cancers."}],"offLabel":[],"totalMarketed":27,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT06241326","title":"Immunotherapy for Hepatocellular Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":11000,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT06431347","title":"Prospective Observational Cohort Study of Transplant and Cell Therapy Candidates and Recipients to Assess Social Determinants of Health","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05420922","title":"Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT06295965","title":"Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT05775419","title":"Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC","phase":"NA","overall_status":"RECRUITING","enrollment_count":1216,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT05326295","title":"Evaluation of Treatment Efficacy by Circulating Tumor Cell Phenotype Surveillance in Breast Cancer Patients","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Hunan Cancer Hospital","has_results":false},{"nct_id":"NCT07417800","title":"Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT05038254","title":"Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":750,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05990946","title":"Smartphone-based Remote Symptom Monitoring to Improve Postoperative Rehabilitation Exercise Adherence After Video-assisted Thoracic Surgery (VATS) for Lung Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":736,"lead_sponsor_name":"Zhongshan People's Hospital, Guangdong, China","has_results":false},{"nct_id":"NCT06641713","title":"HAIC Compared With TACE in Huge Hepatocellular Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":664,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07463651","title":"MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":594,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT06041776","title":"Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":570,"lead_sponsor_name":"Betta Pharmaceuticals Co., Ltd.","has_results":false},{"nct_id":"NCT07277192","title":"HAIC vs. TACE Combined With ICIs and TKIs in Intermediate-to-Advanced HCC: A Multicenter Study on Liver Injury and Survival","phase":"","overall_status":"COMPLETED","enrollment_count":562,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT03712969","title":"Shenlingcao Oral Liquid for Patients With Stage II or IIIA NSCLC","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":527,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT03829969","title":"Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":514,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":true},{"nct_id":"NCT07166003","title":"Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT03563482","title":"Correlation of Metabolic Imaging With Immune Markers in NSCLC Candidate to Immunotherapy.","phase":"NA","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Istituto Clinico Humanitas","has_results":false},{"nct_id":"NCT07424157","title":"Long-Term Follow-Up of Subjects Treated With Seattle Children's Therapeutics Gene Therapy Products","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Seattle Children's Hospital","has_results":false},{"nct_id":"NCT05815082","title":"ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":490,"lead_sponsor_name":"Sixth Affiliated Hospital, Sun Yat-sen University","has_results":false},{"nct_id":"NCT06644430","title":"Ablation of Pulmonary Oligometastasis Combined With System for Advanced Hepatocellular Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":470,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06673459","title":"BuCy Vs. TBICy for Allo-HSCT in T-ALL Patients","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":430,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT06903312","title":"Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":409,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT03668496","title":"A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":390,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT06190782","title":"Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":354,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT07373899","title":"Comparison of the Effect of Surgical Resection Based on Lesion Extent Before and After Neoadjuvant Therapy in Patients With Stage II-IIIB Non-Small Cell Lung Cancer: A Single-Center, Real-World, Open-Label Study.","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":354,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT05797077","title":"Postoperation Maintenance Therapy for Resectable Liver Metastases of Colorectal Cancer Guided by ctDNA","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":346,"lead_sponsor_name":"Sixth Affiliated Hospital, Sun Yat-sen University","has_results":false},{"nct_id":"NCT06457906","title":"SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":340,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT04161287","title":"Comparison of Efficacy in SBRT of HCC ≤5 cm With or Without TACE","phase":"","overall_status":"UNKNOWN","enrollment_count":330,"lead_sponsor_name":"Beijing 302 Hospital","has_results":false},{"nct_id":"NCT06898398","title":"TACE Combined Surgery for the Resectable Huge HCC","phase":"","overall_status":"RECRUITING","enrollment_count":326,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06298123","title":"Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma: Risk Factor Analysis and Prognostic Modelling","phase":"","overall_status":"COMPLETED","enrollment_count":304,"lead_sponsor_name":"Chen Xiaoping","has_results":false},{"nct_id":"NCT07260370","title":"The Difference of microRNA and Circulating Tumor Cells in Blood Among Cancer Patients With Immunotherapy","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT06333561","title":"HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07329920","title":"Mesenchymal CTC Ratio Dynamics Predicts Response and Survival in Pancreatic Ductal Adenocarcinoma With Neoadjuvant/Conversion Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Guo ShiWei","has_results":false},{"nct_id":"NCT07088354","title":"Deep Learning Model Predicts Pathological Complete Response of Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT04521153","title":"Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":294,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT07186621","title":"Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":286,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT01851395","title":"Rapid Autopsy and Procurement of Cancer Tissue","phase":"","overall_status":"RECRUITING","enrollment_count":275,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07269587","title":"A Real-world Study on the Treatment of Adult B-cell Acute Lymphoblastic Leukemia With CNCT-19","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":275,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT06102395","title":"Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":272,"lead_sponsor_name":"Beijing Tongren Hospital","has_results":false},{"nct_id":"NCT06172205","title":"Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":262,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT06864221","title":"Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":260,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT06535607","title":"Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":257,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06631326","title":"HAIC in Combination With PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)","phase":"","overall_status":"COMPLETED","enrollment_count":244,"lead_sponsor_name":"First Hospital of China Medical University","has_results":false},{"nct_id":"NCT03214003","title":"Twice-daily SIB Radiotherapy Versus Standard Radiotherapy for Patients With SCLC","phase":"NA","overall_status":"COMPLETED","enrollment_count":235,"lead_sponsor_name":"Anhui Shi, MD","has_results":false},{"nct_id":"NCT06958614","title":"Prophylactic PEG-rhG-CSF During cCRT in LA-NSCLC","phase":"","overall_status":"COMPLETED","enrollment_count":213,"lead_sponsor_name":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT04564157","title":"New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":210,"lead_sponsor_name":"Fundación GECP","has_results":false},{"nct_id":"NCT03557749","title":"Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies","phase":"","overall_status":"TERMINATED","enrollment_count":210,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT07309497","title":"Pragmatic Geriatric Assessment Before CAR-T or Bispecific Antibody Therapy to Predict Side Effects and Outcomes in Older Patients (GA-ACT Trial)","phase":"","overall_status":"RECRUITING","enrollment_count":208,"lead_sponsor_name":"University of Zurich","has_results":false},{"nct_id":"NCT01796145","title":"Fibroscan Study in HCC","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":207,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT01186861","title":"Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":205,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}